Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-09-01 DOI:10.1016/j.jacbts.2025.03.009

Rumeysa Basdas MSc , José Manuel Martínez-Cereijo MD, PhD , Ángel L. Fernández MD, PhD , Laura Reija MD , Alba Cabaleiro MSc , Susana Belén Bravo PhD , José R. González-Juanatey MD, PhD , Sonia Eiras PhD

{"title":"Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes","authors":"Rumeysa Basdas MSc , José Manuel Martínez-Cereijo MD, PhD , Ángel L. Fernández MD, PhD , Laura Reija MD , Alba Cabaleiro MSc , Susana Belén Bravo PhD , José R. González-Juanatey MD, PhD , Sonia Eiras PhD","doi":"10.1016/j.jacbts.2025.03.009","DOIUrl":null,"url":null,"abstract":"<div><div>Inflamed epicardial fat (EAT) accumulation around the myocardium and coronaries is a risk factor for cardiovascular disease. Glucagon-like peptide receptor-agonists 1 improves the insulin response and reduces EAT thickness. We aimed to demonstrate the effect of semaglutide on proinflammatory epicardial adipogenesis with paracrine effects on cardiomyocytes. Biopsies or isolated stromal cells from subcutaneous adipose tissue and EAT of 67 patients undergoing open-heart surgery were studied by real-time quantitative polymerase chain reaction, proteomics, and metabolic assays. Adipogenesis assay and paracrine effect over atrial cardiomyocytes determined that semaglutide treatment modulates proinflammatory adiposity markers FABP4 and sPLA2 in epicardial adipogenesis with a paracrine effect in atrial cardiomyocytes.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 9","pages":"Article 101277"},"PeriodicalIF":8.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25001615","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Inflamed epicardial fat (EAT) accumulation around the myocardium and coronaries is a risk factor for cardiovascular disease. Glucagon-like peptide receptor-agonists 1 improves the insulin response and reduces EAT thickness. We aimed to demonstrate the effect of semaglutide on proinflammatory epicardial adipogenesis with paracrine effects on cardiomyocytes. Biopsies or isolated stromal cells from subcutaneous adipose tissue and EAT of 67 patients undergoing open-heart surgery were studied by real-time quantitative polymerase chain reaction, proteomics, and metabolic assays. Adipogenesis assay and paracrine effect over atrial cardiomyocytes determined that semaglutide treatment modulates proinflammatory adiposity markers FABP4 and sPLA2 in epicardial adipogenesis with a paracrine effect in atrial cardiomyocytes.

查看原文本刊更多论文

Semaglutide通过旁分泌作用调节hipsc -心房心肌细胞的促炎性心外膜脂肪形成。

炎症性心外膜脂肪（EAT）积聚在心肌和冠状动脉周围是心血管疾病的危险因素。胰高血糖素样肽受体激动剂1可改善胰岛素反应，减少胃粘膜厚度。我们的目的是证明西马鲁肽对心外膜促炎脂肪生成的影响，以及对心肌细胞的旁分泌作用。通过实时定量聚合酶链反应、蛋白质组学和代谢分析研究67例接受心内直视手术患者皮下脂肪组织活检或分离基质细胞和EAT。脂肪生成实验和对心房心肌细胞的旁分泌作用确定，semaglutide治疗调节心外膜脂肪生成中的促炎脂肪标志物FABP4和sPLA2，并对心房心肌细胞产生旁分泌作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.